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ABSTRACT
Introduction Post- COVID- 19 complications require 
simultaneous characterisation and management to plan 
policy and health system responses. We describe the 
12- month experience of the first UK dedicated post- 
COVID- 19 clinical service to include hospitalised and non- 
hospitalised patients.
Methods In a single- centre, observational analysis, 
we report the demographics, symptoms, comorbidities, 
investigations, treatments, functional recovery, specialist 
referral and rehabilitation of 1325 individuals assessed at the 
University College London Hospitals post- COVID- 19 service 
between April 2020 and April 2021, comparing by referral 
route: posthospitalised (PH), non- hospitalised (NH) and post 
emergency department (PED). Symptoms associated with poor 
recovery or inability to return to work full time were assessed 
using multivariable logistic regression.
Results 1325 individuals were assessed (PH: 547, 41.3%; 
PED: 212, 16%; NH: 566, 42.7%). Compared with the PH 
and PED groups, the NH group were younger (median 
44.6 (35.6–52.8) years vs 58.3 (47.0–67.7) years and 
48.5 (39.4–55.7) years), more likely to be female (68.2%, 
43.0% and 59.9%), less likely to be of ethnic minority 
(30.9%, 52.7% and 41.0%) or seen later after symptom 
onset (median (IQR): 194 (118–298) days, 69 (51–111) 
days and 76 (55–128) days; all p<0.0001). All groups had 
similar rates of onward specialist referral (NH 18.7%, PH 
16.1% and PED 18.9%, p=0.452) and were more likely 
to require support for breathlessness (23.7%, 5.5% and 
15.1%, p<0.001) and fatigue (17.8%, 4.8% and 8.0%, 
p<0.001). Hospitalised patients had higher rates of 
pulmonary emboli, persistent lung interstitial abnormalities 
and other organ impairment. 716 (54.0%) individuals 
reported <75% optimal health (median 70%, IQR 55%–
85%). Less than half of employed individuals could return 
to work full time at first assessment.
Conclusion Post- COVID- 19 symptoms were significant 
in PH and NH patients, with significant ongoing healthcare 
needs and utilisation. Trials of interventions and patient- 
centred pathways for diagnostic and treatment approaches 
are urgently required.
INTRODUCTION
Chronic post- viral sequelae are well known,1 
but the SARS- CoV- 2 pandemic’s scale poses 
an unprecedented threat to long- term 
health.2 3 Initially, funding, research, clinical 
practice and policy emphasised acute, hospi-
talised patients in areas with a high burden of 
COVID- 19 cases and deaths. However, more 
recently, there has been an increasing focus 
on the longer- term effects of acute infection 
(‘Long COVID’ or ‘post- COVID syndrome’), 
including non- hospitalised patients4 5 
(figure 1).
Clinically, long COVID remains a poorly 
defined disease.5 6 To address the healthcare 
needs of an estimated 1.1 million individuals 
with long COVID in the UK7 and the millions 
around the world,8 there is a need to deliver 
clinical care while simultaneously reviewing 
clinical data in ‘learning health system’ 
approaches.9 Research on clinical character-
isation and management has been identified 
Key messages
 ► There is high symptom burden for non- hospitalised 
patients post- COVID- 19, even compared with post- 
hospitalised patients post- COVID- 19.
 ► The significant, long- lasting health and social conse-
quences of SARS- CoV- 2 infection are not confined to 
those who required hospitalisation.
 ► This is the first study to report the baseline char-
acteristics, investigations and outcomes of initial 
assessment of all eligible patients in a dedicated 
multiprofessional post- COVID- 19 service, includ-
ing 547 posthospitalisation, 566 non- hospitalised 
and 212 patients discharged from the emergency 
department.
2 Heightman M, et al. BMJ Open Resp Res 2021;8:e001041. doi:10.1136/bmjresp-2021-001041
Open access
by both recent expert consensus groups and patients as 
a priority area.10
COVID- 19 hospitalisation is associated with a signif-
icant risk of end- organ impact, functional impair-
ment, readmission and mortality.11–13 Recent analysis of 
6- month post- COVID- 19 outcomes in China highlighted 
persistent physical, mental and functional impact during 
follow- up, but excluded non- hospitalised patients.14 
Recent electronic health record (EHR) analyses in 
the USA and Denmark, respectively, suggested major 
healthcare resource implications of long COVID in non- 
hospitalised individuals,15 16 but no studies to date have 
reported on the models of care for long COVID.
More than 80 dedicated post- COVID- 19 assessment 
clinics have been announced in England,17 but many 
centres only started accepting referrals 1 year after the 
first wave of the pandemic. Various care models have been 
proposed through expert and patient consensus,18 19 but 
Figure 1 Post- COVID- 19 assessment in the context of the pandemic. CDC, Centers for Disease Control and Prevention; 
ISARIC 4C, International Severe Acute Respiratory and emerging Infection Consortium (Coronavirus Clinical Characterisation 
Consortium); NHS, National Health Service; NIHR, National Institute of Health Research; PCS, Post COVID Syndrome; 
PHE, Public Health England; RECOVERY, Randomised Evaluation of COVID- 19 Therapy; UCLH, University College London 
Hospitals NHS Foundation Trust.
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real- world data are lacking, particularly in community 
settings, where majority of patients with COVID- 19 and 
long COVID are managed.
In April 2020, we established a dedicated service for 
assessment of post- COVID- 19 complications at Univer-
sity College London Hospitals NHS Foundation Trust 
(UCLH) for both hospitalised and non- hospitalised indi-
viduals. We report the baseline characteristics, clinical 
presentation, management and outcomes of all individ-
uals referred to this specialist clinic following suspected 
or confirmed SARS- CoV- 2 infection over a 12- month 
period.
METHODS
Context of the UCLH post-COVID-19 service
The UCLH post- COVID- 19 service is a one- stop model of 
assessment (by physician and physiotherapist), diagnos-
tics and exercise test to triage need for further specialist 
input, treatment or rehabilitation. It accepts referrals 
from three sources: (1) posthospitalised (PH): postadmis-
sion to UCLH with COVID- 19; (2) non- hospitalised (NH): 
individuals referred from primary care with suspected 
long COVID ≥6 weeks post- SARS- CoV- 2 infection; and 
(3) post emergency department (PED): referral for individ-
uals with persistent symptoms at 4–6 weeks after attend-
ance. As per the British Thoracic Society guidance,20 
postdischarge review in PH patients was at 6 weeks for 
those who received respiratory support via continuous 
positive airway pressure or invasive ventilation, or with 
chest imaging abnormality, and at 12 weeks in all other 
patients. PH patients under the care of other specialist 
services or without chest X- ray abnormalities were not 
routinely booked into the post- COVID- 19 service.
Clinical population
Our analysis included all patients assessed at the UCLH 
post- COVID- 19 service between 20 April 2020 and 25 
April 2021 (figure 2), excluding follow- up assessments 
and individuals who did not attend. Due to restricted 
access to testing during the first wave of the pandemic, 
SARS- CoV- 2 infection was defined by either laboratory 
confirmation (viral positive oropharyngeal/nasopharyn-
geal swab when tested by reverse- transcriptase PCR or 
anti- N antigen IgG detected on convalescent serum) or 
strong clinical suspicion (assessed by both the referring 
and consulting clinicians).21 We followed the Strength-
ening the Reporting of Observational Studies in Epide-
miology criteria (checklist).22
Post-COVID-19 assessment
Clinical assessment was developed by secondary care clini-
cians and therapists and consists of a consultation and 
multiprofessional assessment, delivered primarily face to 
face, or where necessary virtually. An EHR (Epic; Epic 
Systems Corporation, Wisconsin) structured assessment 
tool (accessible via the patient portal before the appoint-
ment and during assessment) was used to record the 
sociodemographics, medical history, current symptoms 
and functional status. Where appropriate, the following 
outcome measures were recorded: percentage of best 
health (as used in other tools; eg, EuroQoL- 5 domain- 5 
level), symptom severity for breathlessness, fatigue, 
cough, sleep disturbance and palpitations, MRC (Medical 
Research Council) Dyspnoea Scale, Post- Traumatic 
Stress Disorder Scale (PTSD), Fatigue Assessment Scale, 
two- item Generalised Anxiety Disorder (GAD- 2), and 
Figure 2 Population undergoing assessment at the post- COVID- 19 assessment clinic. CXR, Chest X- Ray; GP, General 
Practice; ICS, Integrated Care System; UCLH, University College London Hospitals NHS Foundation Trust.
4 Heightman M, et al. BMJ Open Resp Res 2021;8:e001041. doi:10.1136/bmjresp-2021-001041
Open access
two- item Patient Health Questionnaire (PHQ- 2)5 11 13 21 
(online supplemental methods).
Selected patients underwent further investigation at the 
discretion of the clinician or following multidisciplinary 
team meetings with respiratory, cardiology and neurology 
input according to clinical need. These tests included full 
blood count, liver and renal function, D- dimer, troponin 
and NT pro- brain natriuretic peptide (NT- proBNP), as 
well as sit- to- stand test, chest X- ray, Computed Tomog-
raphy Pulmonary Angiography (CTPA) with HRCT 
(High- Resolution Computed Tomography) precontrast, 
ECG, cardiac MRI (cMRI), brain MRI, echocardiog-
raphy and Holter monitoring. Lung function testing was 
unavailable due to local infection control requirements.
Clinical management
After assessment, patients were either discharged to the 
community, booked for further clinical follow- up, and/
or referred for specialist opinion, physical rehabilitation, 
respiratory physiotherapy, fatigue management, voca-
tional support and psychological support. Patients with 
elevated GAD- 2 or PHQ- 2 scores (≥3) were advised on 
self- referral to ‘improving access to psychological thera-
pies’ services.
Data extraction and statistical analysis
Demographic and clinical data at first assessment were 
extracted from the EHR. Age, time since symptom onset 
in days and self- reported percentage of best health were 
recorded as continuous variables, and the presence or 
absence of individual symptoms as binary variables. Self- 
reported ability to return to work, for employed indi-
viduals, was recorded on an ordinal scale (‘Not at all’ to 
‘Full time’). The Index of Multiple Deprivation (IMD) 
decile was derived from each patient’s postcode. We used 
descriptive statistics to summarise the baseline charac-
teristics. Continuous variables are reported as median 
with IQR, while categorical variables are reported as 
frequency (%). For group- wise comparison, we used the 
Kruskal- Wallis test for continuous variables and the χ2 test 
or Fisher’s exact test for categorical variables. We used 
multivariable logistic regression models, adjusted for age 
(modelled as a continuous variable) and gender (male vs 
female as the reference group), to investigate symptoms 
associated with (1) optimal (≥75%) patient- reported 
functional recovery at first presentation and (2) patient- 
reported ability to return to full- time employment at first 
presentation. The model for returning to employment 
excluded those not employed or retired before COVID- 
19. Age and gender were included in the models and all 
recorded symptoms (represented as presence vs absence) 
were available for selection in a backwards stepwise selec-
tion process with a threshold of p<0.05. A sensitivity anal-
ysis also considered time since onset for selection in the 
models. Referral rates of local General Practices (GPs) 
(per 1000 practice population) were determined using 
locally available EHR data for practice size and referring 




The number of referrals to the UCLH post- COVID- 19 
clinic mirrored successive pandemic waves (figure 1). 
Excluding patients who did not attend and who cancelled 
appointments, 1325 patients were reviewed: PH, n=547; 
NH, n=566; and PED, n=212 (figure 2). Of the patients, 
614 (46.3%) were tested for SARS- CoV- 2 infection using 
RT-PCR(reverse transcription polymerase chain reac-
tion), of whom 378 (61.6%) were positive, while among 
those who underwent serological testing (n=241, 18.2%) 
114 (47.3%) were positive. The remaining 470 (35.5%) 
patients had strong clinical suspicion of a prior SARS- 
CoV- 2 infection.
The median age was 49.9 (IQR 40.1–60.1) years, and 
748 (56.5%) were women and 550 (41.5%) were of non- 
white ethnicity. Compared with PH and PED individuals, 
NH individuals were younger (44.6 (IQR 35.6–52.8) years 
vs 58.3 (IQR 47.0–67.7) years and 48.5 (IQR 39.4–55.7) 
years, p<0.001), more likely to be female (68.2% vs 43.0% 
and 59.9%, p<0.001), less likely to be non- white (30.9% 
vs 52.7% and 41.0%, p<0.001) and less likely to live in an 
area of social deprivation (IMD category, median (IQR): 
5 (3–7) vs 4 (2–6) and 4 (3–6), p<0.001) (table 1 and 
online supplemental figure 1). General practice referral 
rates in the catchment population ranged from 0.09 to 
3.64 patients per 1000 practice population, with 49 of 201 
(24.4%) practices referring no patients (online supple-
mental figure 2).
Chronic diseases and risk factors
Hypertension (17.5%), asthma (13.4%), cardiovascular 
disease (12.5%), diabetes (11.8%) and thyroid disease 
(6.6%) were the most common comorbidities. Most 
premorbid chronic diseases were more common among 
PH patients, compared with NH and PED patients, 
except asthma (12.1% vs 14.0% and 15.6%), anxiety 
(3.5% vs 2.7% and 4.7%), depression (2.9% vs 3.0% and 
5.7%) and chronic fatigue syndrome (0.0% vs 1.4% and 
0.9%). Current smoking was uncommon (1.3% overall) 
(table 1). Overall, 86 PH patients died before a post- 
COVID- 19 clinical assessment, with a further two PH 
patients dying after clinical review.
Symptoms and functional status
The median time from symptom onset (of acute SARS- 
CoV- 2 infection) to first clinical assessment was 108 days 
(IQR 61–197), and was delayed in NH patients (194 
(118–298) days) compared with PH patients (69 (51–111) 
days) and PED patients (76 (55–128) days) (p<0.001).
At first visit, the median (IQR) number of reported 
symptoms was 2 (1–4) overall (PH, NH and PED groups: 1 
(0–2), 3 (2–5) and 2 (1–4), p<0.001). The most commonly 
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Table 1 Baseline characteristics of 1325 individuals referred to the post- COVID- 19 assessment clinic
Overall (N=1325) Hospitalised (n=547) Non- hospitalised (n=566) ED (n=212)
P value*n (%) n (%) n (%) n (%)
Age, years
  Median (IQR) 49.9 (40.1–60.1) 58.3 (47.0–67.7) 44.6 (35.6–52.8) 48.5 (39.4–55.7) <0.001
  Range 18–93 18–93 19–85 22–85
Female gender 748 (56.5) 235 (43.0) 386 (68.2) 127 (59.9) <0.001
Ethnicity <0.001
  Ethnic minority 550 (41.5) 288 (52.7) 175 (30.9) 87 (41.0)
  White 655 (49.4) 213 (38.9) 332 (58.7) 110 (51.9)
  Unknown/not stated 120 (9.1) 46 (8.4) 59 (10.4) 15 (7.1)
SARS- CoV- 2 laboratory testing
  RT- PCR 614 (46.3) 448 (81.9) 75 (13.3) 91 (42.9) <0.001
  Positive where tested 378 (61.6) 322 (71.9) 12 (16.0) 44 (48.4) <0.001
  Serology 241 (18.2) 28 (5.1) 162 (28.6) 51 (24.1) <0.001
  Positive where tested 114 (47.3) 17 (60.7) 70 (43.2) 27 (52.9) 0.153
  No testing performed 470 (35.5) 71 (13.0) 329 (58.1) 70 (33.0) <0.001
IMD decile
  Median (IQR) 4 (3–6) 4 (2–6) 5 (3–7) 4 (3–6) <0.001
  Unknown 4 (0.3) 2 (0.4) 2 (0.4) 0 (0.0) ~1.000
Chronic diseases and risk factors
  Cardiovascular disease 165 (12.5) 138 (25.2) 16 (2.8) 11 (5.2) <0.001
  Hypertension 232 (17.5) 177 (32.4) 32 (5.7) 23 (10.8) <0.001
  Asthma 178 (13.4) 66 (12.1) 79 (14.0) 33 (15.6) 0.398
  Diabetes mellitus 156 (11.8) 129 (23.6) 13 (2.3) 14 (6.6) <0.001
  Thyroid disease 87 (6.6) 42 (7.7) 31 (5.5) 14 (6.6) 0.333
  Anxiety 44 (3.3) 19 (3.5) 15 (2.7) 10 (4.7) 0.346
  Depression 45 (3.4) 16 (2.9) 17 (3.0) 12 (5.7) 0.139
  Malignancy 55 (4.2) 36 (6.6) 15 (2.7) 4 (1.9) 0.001
  Chronic obstructive pulmonary 
disease
23 (1.7) 17 (3.1) 4 (0.7) 2 (0.9) 0.006
  Chronic kidney disease 19 (1.4) 19 (3.5) 0 (0.0) 0 (0.0) <0.001
  Chronic fatigue syndrome 10 (0.8) 0 (0.0) 8 (1.4) 2 (0.9) 0.009
  Current smoker 17 (1.3) 12 (2.2) 3 (0.5) 2 (0.9) 0.043
Time since symptom onset
  Median, days (IQR) 108 (61–197) 69 (51–111) 194 (118–298) 76 (55–128) <0.001
  0–3 months 559 (42.2) 356 (65.1) 77 (13.6) 126 (59.4)
  3–6 months 387 (29.2) 151 (27.6) 183 (32.3) 53 (25.0)
  6–9 months 164 (12.4) 19 (3.5) 128 (22.6) 17 (8.0)
  9–12 months 168 (12.7) 14 (2.6) 143 (25.3) 11 (5.2)
  12+ months 47 (3.5) 7 (1.3) 35 (6.2) 5 (2.4)
Symptoms†
  Median (IQR) 2 (1–4) 1 (0–2) 3 (2–5) 2 (1–4) <0.001
  Breathlessness 651 (49.1) 211 (38.6) 342 (60.4) 98 (46.2) <0.001
  Fatigue 644 (48.6) 187 (34.2) 359 (63.4) 98 (46.2) <0.001
  Cough 312 (23.5) 106 (19.4) 150 (26.5) 56 (26.4) 0.011
  Chest pain 305 (23.0) 76 (13.9) 176 (31.1) 53 (25.0) <0.001
  Myalgia 251 (18.9) 57 (10.4) 168 (29.7) 26 (12.3) <0.001
  Headache 233 (17.6) 38 (6.9) 166 (29.3) 29 (13.7) <0.001
Continued
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reported symptoms were breathlessness (49.1%), fatigue 
(48.6%), cough (23.5%), myalgia (18.9%), chest pain 
(23.0%), headache (17.6%), ‘brain fog’ (15.1%) and 
palpitations (12.6%). All symptoms were more frequently 
reported by NH patients than PH and PED patients 
(table 1). Overall, 36.1% had MRC Dyspnoea Scale 
score ≥3 (n=593 assessed), 23.8% PTSD score >6 (n=399 
assessed), 29.9% GAD- 2 ≥3 (n=853 assessed) and 24.3% 
PHQ- 2 ≥3 (n=841 assessed), with significant differences 
(p<0.001) between referral sources (table 1). Breathless-
ness, fatigue, palpitations, sleep quality and chest pain 
were more common, and where reported were rated as 
more severe (online supplemental table 3) in the NH 
group compared with the PH group. Symptom co- occur-
rence varied among the groups (figure 3). At first assess-
ment, 716 (54.0%) individuals reported <75% optimal 
health, more frequently in NH (71.8%) compared 
with PED (37.8%) and PH (48.6%) individuals (online 
supplemental table 1).
Investigations
Investigations requested according to clinician judge-
ment included chest X- ray (n=694, 52.4%), echocar-
diography (n=330, 24.9%), Holter monitor (n=222, 
16.8%), CTPA (n=204, 15.4%), 6 min walk test (n=142, 
10.7%), cMRI (for chest pain or troponin elevation, 
n=76, 5.7%) and brain MRI (n=40, 3.0%) (table 2). Of 
204 CTPAs requested, 5.9% (0.9% of cohort) showed 
pulmonary embolism (PE) and 30.9% (4.8% of cohort) 
showed persistent lung interstitial changes. Outside the 
post- COVID- 19 service, 8 patients had PE identified via 
acute medical services and 49 (9.0%) PH patients had 
PE on CTPA during inpatient stay. Echocardiography 
showed left ventricular systolic dysfunction in seven 
patients (2.2% of those examined). cMRI showed mild 
myocarditis in 24 (31.6% of those scanned) and evidence 
of ischaemic heart disease in 11 PH patients (35.5% of 
those scanned). On brain MRI, no changes attributed to 
COVID- 19 were identified. Where tested, NT- proBNP was 
raised in 8.0% of individuals, absolute eosinophil count 
Overall (N=1325) Hospitalised (n=547) Non- hospitalised (n=566) ED (n=212)
P value*n (%) n (%) n (%) n (%)
  Brain fog‡ 200 (15.1) 35 (6.4) 136 (24.0) 29 (13.7) <0.001
  Palpitations 167 (12.6) 31 (5.7) 104 (18.4) 32 (15.1) <0.001
  Arthralgia 170 (12.8) 40 (7.3) 110 (19.4) 20 (9.4) <0.001
  Disturbed sleep 142 (10.7) 25 (4.6) 92 (16.3) 25 (11.8) <0.001
  Anosmia 122 (9.2) 29 (5.3) 78 (13.8) 15 (7.1) <0.001
  Postural symptoms 105 (7.9) 14 (2.6) 74 (13.1) 17 (8.0) <0.001
  Diarrhoea 82 (6.2) 20 (3.7) 56 (9.9) 6 (2.8) <0.001
  Skin rash 75 (5.7) 12 (2.2) 47 (8.3) 16 (7.5) <0.001
  Abdominal pain 75 (5.7) 13 (2.4) 51 (9.0) 11 (5.2%) <0.001
Functional status
  % best health, median (IQR) 
(n=1325)
70 (55–85) 80 (65–95) 60 (50–75) 75 (60–90) <0.001
  Fatigue Assessment Scale score, 
median (IQR) (n=806)
29 (21–37) 24 (16–34) 30 (24–38) 28 (23–36) <0.001
  MRC Dyspnoea Scale score 
assessed
593 (44.8) 192 (35.1) 324 (57.2) 77 (36.3) <0.001
  MRC Dyspnoea Scale score ≥3 
where assessed
214 (36.1) 69 (35.9) 115 (35.5) 30 (39.0) 0.849
  PTSD score assessed 399 (30.1) 151 (27.6) 200 (35.3) 48 (22.6) <0.001
  PTSD score ≥6 where assessed 95 (23.8) 30 (19.9) 53 (26.5) 12 (25) 0.345
  GAD- 2 score assessed 853 (64.4) 295 (53.9) 454 (80.2) 104 (49.1) <0.001
  GAD- 2 score ≥3 where assessed 255 (29.9) 63 (21.4) 159 (35.0) 33 (31.7) <0.001
  PHQ- 2 score assessed 841 (63.5) 287 (52.5) 451 (79.7) 103 (48.6) <0.001
  PHQ- 2 score ≥3 where assessed 204 (24.3) 54 (18.8) 119 (26.4) 31 (30.1) 0.022
*Kruskal- Wallis test used for continuous variables. χ2 test used for categorical variables. Fisher’s exact test used for categorical variables where one 
or more frequencies <5.
†Commonly reported symptoms as shown in the online supplemental material.
‡‘Brain fog’ encompasses problems with memory, cognition and concentration.
ED, emergency department; GAD- 2, two- item Generalised Anxiety Disorder; IMD, Index of Multiple Deprivation; MRC, Medical Research Council; 
PHQ- 2, two- item Patient Health Questionnaire; PTSD, Post- Traumatic Stress Disorder Scale; RT- PCR, Reverse Transcription Polymerase Chain 
Reaction.
Table 1 Continued
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in 5.8%, troponin T in 13.4%, creatine kinase in 16.9%, 
alanine transaminase in 18.0% and D- dimer in 18.9%. 
Abnormal blood investigations were more common in 
PH than in NH individuals (D- dimer: 28.3% vs 10.3%; 
troponin T: 27.0% vs 4.7%; NT- proBNP: 17.0% vs 0.0%; 
and eosinophil count: 6.8% vs 2.5%) (online supple-
mental table 2).
Outcomes and onward referrals
Of the individuals, 740 (55.8%) were discharged after 
first assessment (61.8%, 50.9% and 53.8% in PH, 
NH and PED individuals). Individuals who required 
follow- up had longer symptom duration at presentation 
(median 126, IQR 70–221 days) than those discharged 
at first visit (median 98, IQR 58–170 days). PH, NH 
and PED individuals had similar specialist referral rates 
(16.1%, 18.7% and 18.9%, p=0.452), most commonly 
to cardiology (8.3%) and neurology (9.4%) (table 2). 
Of 776 (58.6% of the study population) individ-
uals assessed by physiotherapists, 363 (46.8%) were 
discharged with self- management support at first visit. 
NH individuals were more likely than PH and PED 
individuals to require support for disordered breathing 
pattern (23.7%, 5.5% and 15.1%, p<0.001) and referral 
for fatigue management (25.4%, 11.0% and 12.0%, 
p<0.001) (table 2).
Optimal health and employment
In the PH, NH and PED groups, the median self- reported 
proportion with optimal health was 80% (65%–95%), 
60% (50%–75%) and 75% (60%–90%), respectively, 
correlating negatively with symptom duration at the time 
of assessment (table 1 and online supplemental figure 3). 
Overall, less than half of employed individuals felt able 
to return to work full time at first assessment (online 
supplemental table 1).
In the multivariable logistic regression analysis 
(table 3), younger age was associated with return to 
work (PH and NH) and male gender (PH and PED). 
For PH individuals, fatigue, brain fog, chest pain and 
breathlessness were associated with inability to work 
full time. Arthralgia and headache were associated with 
full- time return to work. For NH individuals, fatigue, 
brain fog and headache were associated with inability 
to return to work. For PED individuals, breathlessness 
and myalgia were associated with non- return to work, 
whereas cough and arthralgia were associated with 
return to work. For some included symptoms, the 95% 
CIs were wide, suggesting uncertainty about their effect, 
perhaps due to the small number of patients with that 
symptom. Older age and male gender were associated 
with return to optimal health status (≥75%). Fatigue 
and postural symptoms were significantly associated 
with suboptimal (<75%) health status in the PH and 
NH groups, and brain fog in the NH and PED groups 
Figure 3 Co- occurrence of symptoms at first assessment of 1325 individuals referred to the post- COVID- 19 assessment 
clinic. ED, emergency department.
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(table 3). Postural symptoms were rare in PH patients, 
and few with this symptom achieved optimal health. 
The extreme OR probably reflected the small number 
recovering in this group, rather than the importance of 
this symptom. Sensitivity analyses including time since 
onset in the backwards selection process only changed 
the models for recovery in NH patients, where longer 
times since onset and disturbed sleep were associated 
with lower odds of recovery, replacing postural symp-
toms in the model.
Table 2 Investigations, outcomes and onward referrals of 1325 individuals referred to the post- COVID- 19 assessment clinic
Overall (N=1325) Hospitalised (n=547) Non- hospitalised (n=566) ED (n=212)
P value*n (%) n (%) n (%) n (%)
Investigations
Chest X- ray 694 (52.4) 355 (64.9) 204 (36.0) 135 (63.7) <0.001
CT pulmonary angiogram with 
HRCT precontrast
204 (15.4) 104 (19.0) 64 (11.3) 36 (17.0) 0.001
  Pulmonary embolism detected on 
scans performed
12 (5.9) 9 (8.7) 1 (1.6) 2 (5.6) 0.159
  Persistent interstitial abnormalities 
on scans performed
63 (30.9) 49 (47.1) 8 (12.5) 6 (16.7) <0.001
Echocardiogram 330 (24.9) 121 (22.1) 160 (28.3) 49 (23.1) 0.048
  Ejection fraction <55% in 
investigations performed
7 (2.1) 3 (2.5) 4 (2.5) 0 (0.0) 0.763
Holter monitor 222 (16.8) 51 (9.3) 143 (25.3) 28 (13.2) <0.001
6 min walk test 142 (10.7) 24 (4.4) 98 (17.3) 20 (9.4) <0.001
Cardiac MRI 76 (5.7) 31 (5.7) 33 (5.8) 12 (5.7) 0.992
  Mild myocarditis on scans 
performed
24 (31.6) 9 (29.0) 15 (45.5) 0 (0) 0.008
Brain MR 40 (3.0) 27 (4.9) 9 (1.6) 4 (1.9) 0.004
Lung function 17 (1.3) 8 (1.5) 9 (1.6) 0 (0.0) 0.171
Sleep study 8 (0.6) 3 (0.5) 4 (0.7) 1 (0.5) ~1.000
Sit- to- stand test 749 (56.5) 238 (43.5) 415 (73.3) 96 (45.3) <0.001
  Post- test oxygen saturation 
≤92% in tests undertaken
58 (7.7) 35 (14.7) 18 (4.3) 5 (5.2) <0.001
Discharged at first appointment 98 (58–170) 63 (46–101) 183 (118–329) 72 (51–112) <0.001
At least one follow- up visit 126 (70–221) 80 (59–126) 198 (124–274) 89 (58–172) <0.001
First visit outcomes
  Discharged from clinic 740 (55.8) 338 (61.8) 288 (50.9) 114 (53.8) <0.001
  Specialist referral 234 (17.7) 88 (16.1) 106 (18.7) 40 (18.9) 0.452
  Seen by physiotherapist 776 (58.6) 236 (43.1) 398 (70.3) 142 (67.0) <0.001
  Psychology referrals to iAPT Advised if GAD- 2 or PHQ- 2 elevated (see table 1): patients can self refer to this service.
Specialist referral
  Cardiology 110 (8.3) 41 (7.5) 46 (8.1) 23 (10.8) 0.317
  Neurology 125 (9.4) 26 (4.8) 87 (15.4) 12 (5.7) <0.001
  ENT 31 (2.3) 4 (0.7) 20 (3.5) 7 (3.3) 0.002
  Other 53 (4.0) 19 (3.5) 24 (4.2) 10 (4.7) 0.683
Physiotherapist outcomes 776 (58.6) 236 (43.1) 398 (70.3) 142 (67.0)
  Discharge with self- management 
support†
363 (46.8) 133 (56.4) 152 (38.2) 78 (54.9) <0.001
  Cognitive rehabilitation† 17 (2.2) 5 (2.1) 9 (2.3) 3 (2.1) ~1.000
  Speech and language therapy† 46 (5.9) 31 (13.1) 7 (1.8) 8 (5.6) <0.001
  Respiratory physiotherapy† 
(including ENO)
196 (25.3) 30 (12.7) 134 (33.7) 32 (22.5) <0.001
  Fatigue management† 144 (18.6) 26 (11.0) 101 (25.4) 17 (12.0) <0.001
*Kruskal- Wallis test for continuous variables. χ2 test for categorical variables. Fisher’s exact test used for categorical variables where one or more frequencies <5.
†Percentages reported as % of individuals seen by physiotherapist.
ED, emergency department; ENO, English National Opera 'Breathe' programme; ENT, ear, nose and throat; GAD- 2, two- item Generalised Anxiety Disorder; HRCT, 
High- Resolution Computed Tomography; iAPT, improving access to psychological therapies; PHQ- 2, two- item Patient Health Questionnaire.
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DISCUSSION
Our 12- month experience with the earliest post- 
COVID- 19 clinical service in the UK to include NH, PH 
and PED patients highlights five findings. First, we docu-
ment significant functional impairment across all patient 
groups, particularly NH individuals. Second, we identify 
the need for multidisciplinary, structured assessment 
following SARS- CoV- 2 infection in all patient groups. 
Third, we show variations in symptoms and diagnostic 
features across the patient groups. Fourth, we describe 
a high burden of specialist input, onward therapy and 
psychology support in different patient groups in a real- 
world post- COVID clinical service. Fifth, we identify 
factors which could contribute to inequitable access to 
post- COVID- 19 care.
Our results underscore the patient and system need for 
comprehensive measurement and reporting of effects of 
SARS- CoV- 2 infection in all individuals (PH and NH) 
on health, function and healthcare utilisation, and the 
profound ramifications for the individuals, their families 
and communities beyond measures of functional impair-
ment and organ dysfunction. Patients with long COVID 
have called for ‘recognition, research and rehabilita-
tion’,23 but COVID- 19 research and care have focused 
primarily on acute physiology, management and mortality 
among hospitalised individuals. It has been previously 
established that the burden of specific diseases can only 
be compared across population groups when morbidity 
in addition to mortality is accurately recorded.24 The 
burden of long COVID must be documented in this way.
The extent of multimorbidity and functional impair-
ment in long COVID requires cross- specialty, multiprofes-
sional, integrated working, and development of broader 
clinical expertise, with transferable benefits to other 
conditions beyond the pandemic,21 rather than siloed, 
organ- based approaches.19 25 Such integrated care path-
ways have been effective in other diseases prepandemic26 
and could support rapid upskilling and skills transfer-
ence needed for the wider workforce in post- COVID- 19 
clinical care. To enable a consistent, holistic approach, 
Table 3 Multivariable logistic regression analysis showing symptoms associated with ability to return to work full time 
and ≥75% functional recovery at first assessment of 1325 individuals referred to the post- COVID- 19 assessment clinic
Return to work full time (n=1028) ≥75% functional recovery (n=1325)
Covariate
Multivariable OR 
(95% CI) P value Covariate
Multivariable OR 
(95% CI) P value
Hospitalised     
  Age 0.97 (0.95 to 0.99) 0.008 Age 1.01 (1.00 to 1.03) 0.019
  Male gender 1.88 (1.33 to 2.67) <0.001 Male gender 2.58 (1.94 to 3.42) <0.001
  Brain fog 0.13 (0.03 to 0.58) 0.008 Postural 
symptoms
0.05 (0.01 to 0.46) 0.007
  Chest pain 0.28 (0.13 to 0.60) 0.001 Chest pain 0.43 (0.25 to 0.74) 0.002
  Fatigue 0.29 (0.17 to 0.52) <0.001 Fatigue 0.47 (0.33 to 0.68) <0.001
  Breathlessness 0.54 (0.33 to 0.90) 0.019 Arthralgia 2.69 (1.22 to 5.92) 0.014
  Arthralgia 2.55 (1.01 to 6.42) 0.048   
  Headache 2.75 (1.04 to 7.25) 0.041   
Non- hospitalised     
  Age 0.98 (0.96 to 0.99) 0.008 Age 1.02 (1.00 to 1.04) 0.018
  Male gender 1.20 (0.84 to 1.74) 0.319 Male gender 1.44 (0.99 to 2.09) 0.058
  Brain fog 0.54 (0.35 to 0.86) 0.008 Postural 
symptoms
0.08 (0.02 to 0.32) <0.001
  Headache 0.64 (0.42 to 0.97) 0.034 Fatigue 0.49 (0.35 to 0.68) <0.001
  Fatigue 0.67 (0.5 to 0.92) 0.012 Myalgia 0.49 (0.30 to 0.81) 0.005
    Brain fog 0.53 (0.31 to 0.89) 0.017
Emergency 
department
    
  Age 0.98 (0.95 to 1.01) 0.155 Age 1.01 (0.99 to 1.04) 0.266
  Male gender 1.79 (1.04 to 3.10) 0.037 Male gender 2.98 (1.78 to 4.98) <0.001
  Breathlessness 0.25 (0.13 to 0.48) <0.001 Brain fog 0.29 (0.1 to 0.85) 0.025
  Myalgia 0.26 (0.09 to 0.75) 0.013 Fatigue 0.40 (0.24 to 0.67) 0.001
  Cough 2.71 (1.28 to 5.74) 0.009   
  Arthralgia 3.92 (1.12 to 13.77) 0.033   
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we developed structured EHR tools to capture functional 
and psychological impact. We implemented multispe-
cialty, multidisciplinary meetings to enhance efficiency 
and share learning, seeking patient feedback from all 
encounters to improve services. Further analysis of the 
correlation between symptoms, functional consequences 
and investigations via data- driven approaches are essen-
tial to guide mechanistic studies, treatment approaches 
and risk stratification. Hospital- based and clinic- based 
analyses are important given the slow uptake of new long 
COVID coding in primary care.27
As in other studies, we document severe functional 
impairment11–13 and significant mortality risk post 
hospital discharge. We also document severe functional 
impairment in NH and PED individuals despite low 
predicted2 and observed mortality risk. UK guidance for 
posthospital follow- up prioritised those requiring greater 
levels of organ support or with more severe chest imaging 
abnormality.20 This focus risks lack of recognition of 
morbidity in patients with less severe acute respiratory 
presentations of SARS- CoV- 2 infection. The multivariable 
models suggested that fatigue, brain fog, chest pain and 
breathlessness were the common factors for continued 
suboptimal health and not returning to work. Other 
factors were less consistently included in the models and 
some were associated in an unexpected direction, which 
may be due to a real effect or confounding with other 
symptoms. Underlying mechanisms and management 
require further research.
Like other studies, we show prolonged variation in 
symptoms and extent of diagnostic abnormality between 
different cohorts, suggesting different phenotypes of 
post- COVID- 19 syndrome/long COVID.28 Absence of a 
specific diagnostic test or biomarker29 makes the balance 
between adequate investigation of significant symp-
toms and ‘over- medicalising’ challenging. For example, 
elevated D- dimer levels triggered frequent CTPA requests, 
but with low diagnostic yield in NH patients. Exercise 
testing showed oxygen desaturation most frequently 
in PH patients, but also in the NH group without clear 
evidence of lung or heart abnormalities. Echocardiog-
raphy rarely showed abnormal findings despite frequent 
use to investigate chest pain and breathlessness. The clin-
ical significance of detectable abnormalities on cMRI in 
patients with chest pain requires further evaluation.30 
Future research must determine whether and how diag-
nostic abnormalities relate to end- organ effects or mech-
anisms underlying long COVID.
Patients often needed further specialist opinion and 
onward referral to community rehabilitation and psycho-
logical support, with significant resource implication 
given such pathways are currently poorly defined. In addi-
tion to the ongoing waves of COVID- 19 infection, threats 
of new variants and effects on non- COVID- 19 services,2 
the ‘long tail’ of the pandemic in terms of long COVID 
is a concern for policy and health service planning in all 
countries. Rehabilitation needs are complex and likely 
to require novel multimodal therapy approaches which 
integrate psychological support and workforce capacity 
and capability, which are not currently in place. Exper-
tise in fatigue management, treatment for disordered 
breathing patterns and programmes to support return 
to employment are particular priorities. Novel digital 
self- management solutions could be a useful adjunct 
but need further evaluation. Although different post- 
COVID- 19 care models are evolving,31 32 the evidence 
base is minimal, with few, large- scale, pragmatic trials 
of treatment and rehabilitation. Developing integrated, 
research- oriented pathways in EHR- enabled health 
systems could provide a platform for rapid evaluation of 
investigation, treatment and rehabilitation approaches 
alongside delivering care, which has been effective in 
acute COVID- 19.33
There are signs of inequitable access to care in our 
cohort. Although the observed ethnicity of NH patients 
reflected the catchment population, it contrasted with 
the disproportionate burden of acute SARS- CoV- 2 in 
ethnic minorities. NH patients were also less likely to live 
in areas of deprivation and may have had easier access to 
referral. Varying referral rates by primary care provider 
were seen, requiring further investigation to understand 
contributing factors. Underdiagnosis of long COVID has 
been described in primary care in England.32 NH patients 
had delayed referral. Consideration should be given to 
proactive follow- up of patients managed in the commu-
nity, particularly given the severity of illness in patients 
referred. Follow- up strategies should also account for 
the needs of frail, elderly, comorbid and hard- to- reach 
patients, who were under- represented in our cohort.
Our findings have several limitations. We report 
outcomes from a single centre, unlikely to be representa-
tive of the whole UK population. As post- COVID- 19 clinics 
are established around the UK and in other countries, 
prospective data collection and comparison will enable 
variations to be investigated. We used subjective symptom 
and functional status data, which may have self- reporting 
bias. We report real- world, clinical findings and therefore 
data regarding premorbid status, baseline characteristics, 
investigations and follow- up (particularly for patients 
with persistent disease for 12 months or more) are more 
limited than in dedicated research cohorts. NH patients 
were self- selecting while PH patients were included as 
part of routine follow- up. This selection bias precludes 
both making precise estimates of the burden of long 
COVID among NH patients and also making compari-
sons between NH patients and other patient groups. In 
our basic logistic regression models, we modelled age as a 
linear variable, which may have obscured true non- linear 
effects of age in these models. Our models were based on 
cross- sectional data at presentation to the clinic. We did 
not include a control population. Although it is possible 
that a proportion of patients would present with ‘medi-
cally unexplained symptoms’,34 we only included patients 
referred to the post- COVID- 19 assessment service with 
clinical or serological confirmation of SARS- CoV- 2 
infection. Moreover, there is evidence that long- term 
Heightman M, et al. BMJ Open Resp Res 2021;8:e001041. doi:10.1136/bmjresp-2021-001041 11
Open access
symptoms are significantly higher in individuals who 
are PCR- positive for SARS- CoV- 2, compared with PCR- 
negative individuals,35 and higher in individuals with 
long COVID compared with postinfluenza.36
Our findings have several implications for research 
and policy. First, we identified differences in the longer- 
term effects of SARS- CoV- 2 infection in PH versus NH 
individuals, supporting the existence of a number of 
different phenotypes of long COVID. Further correlation 
of symptom clusters, functional impact and diagnostic 
information is required to better define phenotypes and 
to inform studies of underlying mechanisms and poten-
tial treatments. Second, a wide range of patient- reported 
outcome measures were required to capture the impact of 
long COVID on individuals. Development of a validated 
clinical assessment tool will further enable investigation 
of the natural history of the condition across larger data 
sets and differing EHR systems. Third, we identified the 
need for a novel model of rehabilitation, incorporating 
psychological support and urgent solutions to address 
the current workforce shortfalls. Fourth, the multi-
system nature of the condition will require broadening 
of clinical expertise both within primary and secondary 
care and effective integrated pathways. Finally, given the 
severity of illness documented in all patient groups, our 
analysis supports the need for swift, equitable access to 
assessment for all patients suffering from ongoing illness 
after SARS- CoV- 2 infection, as well as effective infection 
suppression policy for all.
Post- COVID- 19 morbidity can be severe, regardless of 
severity of acute illness, and the scale of healthcare util-
isation and inability to return to employment represent 
a major burden to individuals, healthcare and welfare 
systems, and economies. Definition of long COVID 
phenotypes and development and evaluation of diag-
nostic, treatment and rehabilitation approaches are 
urgently required. Dissemination of clinical expertise in 
the management of post- COVID- 19 complications needs 
to occur across integrated care systems and policy change 
is required to improve equity of access by individuals to 
appropriate levels of care and support.
Patient and public involvement
Patient views were incorporated in the development of 
the clinical pathways since inception, and two patients 
have been involved in the writing and review of the final 
manuscript (EA and LH). The views expressed by patient 
groups in meetings attended by MH and TEH (eg, NHS 
England’s Long COVID Taskforce, Department of Health 
and Social Care’s Long COVID Round Table) informed 
the study objectives and design, and through EA and LH 
the views of wider patient groups (ie, LongCOVIDSOS 
and UKDoctors#Longcovid) were also incorporated.
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